de Menthon, Mathilde <br/><br/>
Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients.  [electronic resource] 

 -  Clinical and experimental rheumatology   
 - S63-71 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0392-856X 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Murine-Derived--adverse effects<br/>Chi-Square Distribution<br/>Drug Resistance<br/>Drug Substitution<br/>Female<br/>France<br/>Granulomatosis with Polyangiitis--diagnosis<br/>Humans<br/>Immunosuppressive Agents--adverse effects<br/>Infliximab<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Patient Selection<br/>Prospective Studies<br/>Recurrence<br/>Remission Induction<br/>Risk Assessment<br/>Risk Factors<br/>Rituximab<br/>Severity of Illness Index<br/>Time Factors<br/>Treatment Outcome<br/>Young Adult